Institutul Regional De Oncologie Iasi — Clinical Trial Site

82 Registered trials

50 Currently recruiting

Organisation

Institutul Regional De Oncologie Iasi

Location

Iasi, Romania

Identifier

ORG-100037039

Address

Strada Sarariei 177b, 707023, Romania

Departments

-
0029: Oncology
040007: Oncology
164204: Hematology
3304: Hematology
Departamentul de Oncologie Medicala
Dept. of Oncology
Hematologie
Hematology
Hematology Clinic
Hematology department
Medical Oncology
N/A
Oncologie
Oncologie Medicala
Oncology
Oncology Department
Sectia Hematologie
Sectia Oncologie Medicala
Sectie Exterioara – Spitalizare de zi

Clinical trials at this site (82)

Search interface

A Study of Navlimetostat (BMS986504) in Participants with Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer with Homozygous MTAP… Recruiting

2024-519814-29-00 Advanced or Metastatic Non-small Cell Lung Cancer 4 2025-09-12
A phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in AML patients undergoing… Recruiting

2024-512752-38-00 Adjunctive and maintenance treatment to HCT 5 2025-09-09
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting

2024-515884-69-00 Extensive Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-07-16
A Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy in Participants with Non-s… Recruiting

2024-513682-40-01 Non-squamous (NSQ), Stage IV or Recurrent Non-small Cel 5 2025-07-04
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Locally Advanced or Metastatic Non-small Cell Lung Canc 5 2025-06-12
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Unresectable, Locally Advanced or Metastatic HER2 posit 5 2025-06-10
A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C… Recruiting

2024-517422-25-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-05-22
A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting

2023-506327-29-00 Non-Small Cell Lung Cancer 5 2025-05-14
A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido… Recruiting

2024-515279-37-00 Relapsed or Refractory and Lenalidomide exposed Multipl 5 2025-04-17
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting

2024-515566-13-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2025-03-19
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting

2024-513853-66-00 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or 5 2025-02-04
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate… Recruiting

2024-511309-47-00 moderate thrombocytopenia 4 2024-07-17
A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un… Recruiting

2023-508613-17-00 Neoplasms, Head and Neck 5 2024-05-29
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics o… Recruiting

2022-502193-16-00 Chronic lymphocytic leukemia, Multiple Myeloma and Non- 5 2023-11-14
Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting

2022-501515-14-00 Newly Diagnosed Multiple Myeloma (NDMM) 5 2023-09-29
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies Recruiting

2023-504931-42-00 Chronic lymphocytic leukemia/Small lymphocytic lymphoma 4 2021-04-06
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting

2023-504201-36-00 Defined by parent protocol. The study will enroll all a 10 2018-12-21